生命科学资讯
生物技术与制药领域的最新动态
FDA slams ExThera with warning letter over controversial blood filter device
创下2024年以来最大规模生物科技IPO,纳斯达克上市募资4亿美元
Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing
赛默飞世尔推出抗排异药物剂量辅助检测方案。
Thermo Fisher unveils test to aid in dosing of antirejection drug
Earendil签署8.85亿美元协议,采用药明合联连接技术开发新一代ADC药物。
Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
临床试验空间生物标志物组合
Spatial Biomarker Panels for Clinical Trials
随着CAR-T细胞疗法在实体瘤领域取得进展,监管繁文缛节阻碍发展步伐。
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
'如同对牛弹琴':参议院听证会直指FDA罕见病审批流程问题
'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
Sarepta首席执行官道格·英格拉姆在杜氏肌营养不良症领域取得突破与争议十年后宣布退休。
Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
分析师看好MDMA药物潜力,AtaiBeckley焦虑试验报告改善显著。
Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
勃林格殷格翰与英国生物科技公司达成5亿美元协议,开发口服自身免疫疾病疗法。
Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
百时美施贵宝8亿美元ADC药物在乳腺癌三期试验中达到主要生存终点。
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial
Quantum Surgical收购强生旗下NeuWave Medical,获得微波消融技术。
Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology
主角计划从武田制药获利4亿美元,而非分享美国鲁斯费肽利润。
Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
Accent因不良事件暂停实体瘤试验,转向其他主要癌症项目。
Accent halts solid tumor trial over adverse events, pivots to other lead cancer program
旭化成以9.2亿美元收购德国Aicuris,强化研发组合
Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost
ARPA-H拨款高达1.44亿美元用于抗衰老医学研究
ARPA-H designates up to $144M for anti-aging medical research
担忧特朗普的最惠国待遇推进将“摧毁生物技术创新”,中型企业组建联盟反击。
Worried Trump's MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back
查尔斯河出售制造与发现业务,兑现战略转型承诺。
Charles River sells manufacturing and discovery businesses to fulfill promised pivot
诺和诺德与朗格初创公司签署21亿美元协议,以增强口服药物递送能力。
Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess